Vasopressin
An endogenous hypothalamic nonapeptide hormone that regulates water balance, blood pressure, and stress-related memory, and is FDA-approved as a vasopressor for shock.
Vasopressin (arginine vasopressin, AVP) is a nine-amino-acid hormone produced in the hypothalamus that acts through V1a receptors in the vasculature and brain, V1b receptors in the pituitary, and V2 receptors in the renal collecting duct to control blood pressure, fluid retention, and stress responsiveness. In pharmaceutical form it is FDA-approved for central diabetes insipidus and as a vasopressor in septic and vasodilatory shock. In the central nervous system it functions as a neuromodulator involved in social recognition, stress-related memory encoding, and hippocampal synaptic plasticity, and intranasal delivery for cognitive or social applications remains investigational with limited and mixed human evidence.
Class
Endogenous nonapeptide hormone
Half-life
10-20 minutes
Routes
Intranasal, Subcutaneous, Intravenous
Category
Hormone & Reproductive
Researched benefits
What it's studied for
Vasopressor support in shock
Through V1a receptors in vascular smooth muscle, vasopressin raises systemic vascular resistance and blood pressure. It is a standard vasopressor at roughly 0.03-0.04 units/minute IV in septic and vasodilatory shock refractory to catecholamines.
Water balance and antidiuresis
V2 receptor activation in the renal collecting duct promotes water reabsorption, giving vasopressin its antidiuretic (fluid-retention) action and its role in treating central diabetes insipidus.
Memory consolidation
Preclinical work shows vasopressin facilitates long-term potentiation in hippocampal circuits, and V1 receptor signaling in the dentate gyrus enhances neuronal excitability, providing a cellular basis for its modulation of learning and memory.
Social recognition and behavior
As a central neuromodulator, vasopressin influences social recognition and social memory; a randomized fMRI study found intranasal AVP altered conciliatory and cooperative behavior in a strongly sex-dependent manner.
Blood pressure regulation
Animal studies removing the vasopressin-secreting neurointermediate pituitary lobe produced sustained blood-pressure lowering and normalized hypertension, underscoring vasopressin's role in cardiovascular homeostasis beyond water balance.
Mechanism
How it works
Vasopressin is a nonapeptide synthesized by magnocellular and parvocellular neurons of the hypothalamus and released from the posterior pituitary. It signals through three G-protein-coupled receptor subtypes: V1a in vascular smooth muscle and brain (vasoconstriction, social behavior, and memory), V1b in the anterior pituitary (ACTH release and stress responses), and V2 in the renal collecting duct (antidiuresis via water reabsorption).
In the vasculature, V1a activation increases intracellular calcium in smooth muscle, producing vasoconstriction and raised systemic vascular resistance, which underlies vasopressin's clinical use as a vasopressor. In the kidney, V2 receptor signaling drives insertion of aquaporin water channels in the collecting duct, concentrating urine and retaining fluid.
In the central nervous system, vasopressin acts as a neuromodulator that enhances hippocampal synaptic plasticity. Rat hippocampal slice studies show AVP depolarizes dentate gyrus granule cells via V1b receptor and PLCβ-mediated depletion of PIP2, which depresses ATP-sensitive potassium channels and facilitates long-term potentiation at perforant path synapses, linking vasopressin to hippocampal-dependent learning and memory.
Vasopressin's cognitive and social effects appear state-dependent and are mediated by complex V1a receptor signaling in the hippocampus and amygdala, with effects most evident in stress contexts. Compared with desmopressin, a V2-selective analog used for antidiuretic indications, vasopressin's V1a activity brings vasoconstriction, hypertension, and cardiac effects, so the two are not interchangeable.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Clinical (vasopressor)
- Dose
- 0.03-0.04 units/minute
- Frequency
- Continuous infusion
- Timing
- Titrated to blood pressure
- Duration
- As clinically indicated
- Route
- Intravenous
Standard vasopressor regimen in septic and vasodilatory shock refractory to catecholamines; administered only in critical-care settings.
Investigational (intranasal)
- Dose
- Not established
- Frequency
- Not established
- Timing
- Study-dependent
- Duration
- Study-dependent
- Route
- Intranasal
Intranasal AVP has been used as a research tool for social and memory studies; no validated dosing exists for cognitive enhancement and the compound is not commercially available in Western markets for this use.
- Vasopressin is a prescription drug administered under medical supervision; the IV vasopressor use belongs strictly to critical-care settings.
- For antidiuretic indications such as diabetes insipidus and nocturia, desmopressin is used instead of vasopressin to avoid V1a-mediated vasoconstriction and cardiac effects.
- Human evidence for intranasal vasopressin as a cognitive enhancer in healthy adults is very limited and inconsistent.
Evidence
Research & clinical studies (7)
Effects of septic shock vasopressors on the fitness of Escherichia coli
Across 21 diverse E. coli strains, vasopressin showed low to no effect on bacterial growth and virulence, unlike norepinephrine, suggesting a more microbiome-neutral profile in sepsis management.
PMID 42203850Genetic Insights Into AVP Deficiency: Identification of a Novel AVP Variant and Compilation of a Curated Catalogue of Pathogenic Variants
Identified a novel AVP gene mutation (c.122G>A, p.(Cys41Tyr)) causing central diabetes insipidus in two families and compiled 110 known pathogenic AVP variants into a curated reference resource.
PMID 42212497Tracing the impact of electrophysiological studies of magnocellular neurons
Electrophysiological studies of supraoptic magnocellular neurons linked their electrical activity to physiological function, advancing mechanistic understanding of vasopressin and oxytocin regulation.
PMID 42202941Pituitary Neurolobectomy induces sustained hypotension in male Wistar rats and normalizes blood pressure in male spontaneously hypertensive rats
Removing the vasopressin- and oxytocin-secreting neurointermediate pituitary lobe lowered blood pressure in normotensive rats and normalized it in hypertensive rats, showing vasopressin's role in blood-pressure regulation.
PMID 42210729PLCβ-Mediated Depletion of PIP and ATP-Sensitive K Channels Are Involved in Arginine Vasopressin-Induced Facilitation of Neuronal Excitability and LTP in the Dentate Gyrus
In rat hippocampal slices, AVP depolarized dentate gyrus granule cells via V1b/PLCβ-mediated PIP2 depletion, depressing K+ channels and facilitating long-term potentiation, a cellular mechanism for memory modulation.
PMID 35788107Sex differences in the neural and behavioral response to intranasal oxytocin and vasopressin during human social interaction
In a randomized double-blind fMRI study, intranasal AVP increased conciliatory behavior in women and cooperation reciprocation in men, with strongly sex-differentiated neural responses in reward and social-cognition regions.
PMID 24157401Copeptin as a diagnostic tool in a patient with adipsia and hypernatremia
Copeptin measurement during osmotic stimulation identified a selective defect in osmolality-driven vasopressin release in a patient with adipsia and hypernatremia despite intact kidney function.
PMID 42211868Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Hypertension
- Coronary artery disease
- Hyponatremia risk
- Heart failure
V1a receptor activation produces vasoconstriction and can raise blood pressure and stress the heart, so vasopressin carries a moderate risk profile and requires medical supervision. It should not be substituted for desmopressin in antidiuretic indications.
FAQ
Vasopressin — common questions
What is vasopressin?
Vasopressin (arginine vasopressin, AVP) is an endogenous hypothalamic nonapeptide that acts through V1a receptors in the vasculature and brain and V2 receptors in the renal collecting duct to regulate blood pressure, water balance, and stress responsiveness. It is FDA-approved for central diabetes insipidus and as a vasopressor in septic shock, and centrally it acts as a neuromodulator involved in social recognition and hippocampal memory.
What is vasopressin primarily studied for?
It is primarily studied for memory consolidation, social memory, fluid retention, and vasoconstriction.
How is vasopressin different from desmopressin?
Desmopressin is V2-selective, giving antidiuretic action without the vasoconstriction, hypertension, and cardiac effects that vasopressin's V1a activation produces. For antidiuretic indications such as diabetes insipidus and nocturia, desmopressin is used instead of vasopressin, and the two should not be used interchangeably for the same indication.
Is intranasal vasopressin an effective cognitive enhancer?
Evidence is limited and mixed. A 2019 study reported intranasal vasopressin increased social communication in autistic children, but a larger replication trial did not reproduce it, and controlled studies in healthy adults generally show no consistent memory benefit. It remains a research tool rather than a validated cognitive enhancer and is not commercially available in Western markets for this use.
How is vasopressin used clinically?
Its main clinical use is in critical care as a vasopressor, typically at 0.03-0.04 units/minute IV, for septic and vasodilatory shock that is refractory to catecholamines, acting through V1a receptors to increase systemic vascular resistance.
What are the side effects of vasopressin?
Reported considerations include hypertension, coronary artery disease, hyponatremia risk, and heart failure. Because V1a activation causes vasoconstriction and can raise blood pressure and affect the heart, it carries a moderate risk profile and should be used only under medical supervision.
Is vasopressin legal and FDA-approved?
Yes. Vasopressin injection is FDA-approved (brand Vasostrict, NDA 204485, effective April 2014) and indicated for vasodilatory shock, and it appears on the FDA 503A Category 1 compounding list. It is prescription only.
